Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /

Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long­ term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.

Saved in:
Bibliographic Details
Main Authors: Andersson, Borje. editor., Murray, David. editor., SpringerLink (Online service)
Format: Texto biblioteca
Language:eng
Published: Boston, MA : Springer US : Imprint: Springer, 2002
Subjects:Medicine., Cancer research., Oncology., Medicine & Public Health., Cancer Research.,
Online Access:http://dx.doi.org/10.1007/978-1-4615-1173-1
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-TEST:206808
record_format koha
spelling KOHA-OAI-TEST:2068082018-07-30T23:36:37ZClinically Relevant Resistance in Cancer Chemotherapy [electronic resource] / Andersson, Borje. editor. Murray, David. editor. SpringerLink (Online service) textBoston, MA : Springer US : Imprint: Springer,2002.engOver the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long­ term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long­ term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.Medicine.Cancer research.Oncology.Medicine & Public Health.Oncology.Cancer Research.Springer eBookshttp://dx.doi.org/10.1007/978-1-4615-1173-1URN:ISBN:9781461511731
institution COLPOS
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
En linea
databasecode cat-colpos
tag biblioteca
region America del Norte
libraryname Departamento de documentación y biblioteca de COLPOS
language eng
topic Medicine.
Cancer research.
Oncology.
Medicine & Public Health.
Oncology.
Cancer Research.
Medicine.
Cancer research.
Oncology.
Medicine & Public Health.
Oncology.
Cancer Research.
spellingShingle Medicine.
Cancer research.
Oncology.
Medicine & Public Health.
Oncology.
Cancer Research.
Medicine.
Cancer research.
Oncology.
Medicine & Public Health.
Oncology.
Cancer Research.
Andersson, Borje. editor.
Murray, David. editor.
SpringerLink (Online service)
Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
description Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long­ term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.
format Texto
topic_facet Medicine.
Cancer research.
Oncology.
Medicine & Public Health.
Oncology.
Cancer Research.
author Andersson, Borje. editor.
Murray, David. editor.
SpringerLink (Online service)
author_facet Andersson, Borje. editor.
Murray, David. editor.
SpringerLink (Online service)
author_sort Andersson, Borje. editor.
title Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
title_short Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
title_full Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
title_fullStr Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
title_full_unstemmed Clinically Relevant Resistance in Cancer Chemotherapy [electronic resource] /
title_sort clinically relevant resistance in cancer chemotherapy [electronic resource] /
publisher Boston, MA : Springer US : Imprint: Springer,
publishDate 2002
url http://dx.doi.org/10.1007/978-1-4615-1173-1
work_keys_str_mv AT anderssonborjeeditor clinicallyrelevantresistanceincancerchemotherapyelectronicresource
AT murraydavideditor clinicallyrelevantresistanceincancerchemotherapyelectronicresource
AT springerlinkonlineservice clinicallyrelevantresistanceincancerchemotherapyelectronicresource
_version_ 1756268299096686592